文献速递眼底病与葡萄膜炎

双膦酸盐使用相关的NLRP3激活与年龄相关性黄斑变性发病风险

NLRP3 Activation With Bisphosphonate Use and the Risk of Incident Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

在美国退伍军人中开展的回顾性队列研究显示,经倾向评分匹配后,双膦酸盐每多使用一年与年龄相关性黄斑变性(AMD)风险升高4.7%相关(HR 1.047,95%CI 1.020-1.074);在双膦酸盐使用者中,氟西汀或氟伏沙明与AMD发病风险降低相关(HR 0.814,95%CI 0.676-0.98)。

要点

  • 双膦酸盐每多使用一年,AMD风险升高4.7%(HR 1.047,95%CI 1.020-1.074)。
  • 双膦酸盐使用者中,氟西汀或氟伏沙明与AMD风险降低相关(HR 0.814,95%CI 0.676-0.98)。
  • 结果支持NLRP3炎症小体参与AMD发病,并可能成为治疗靶点。

核心结论

  • 双膦酸盐使用增加AMD风险,而NLRP3抑制剂减轻这一效应。
  • 这些发现支持NLRP3炎症小体参与AMD发病的假说,并代表一个潜在的治疗靶点。

研究设计与样本

  • 回顾性队列研究,对象为接受过双能X线吸收测定法(DEXA)扫描的美国退伍军人。
  • 采用时间依赖性Cox模型评估累积双膦酸盐暴露与AMD发病的关联。
  • 应用倾向评分匹配平衡双膦酸盐使用者与非使用者之间的特征。
  • 二次分析在双膦酸盐使用者中考察NLRP3抑制剂(氟西汀和氟伏沙明)对AMD风险的影响。

主要发现

  • 倾向评分匹配后,双膦酸盐每多使用一年与AMD风险升高4.7%相关(HR 1.047,95%CI 1.020-1.074)。
  • 在匹配样本的双膦酸盐使用者中,使用氟西汀或氟伏沙明与AMD发病风险降低相关(HR 0.814,95%CI 0.676-0.98)。

关键数值与推荐

  • 双膦酸盐每多使用一年:HR 1.047(95%CI 1.020-1.074)。
  • 双膦酸盐使用者中氟西汀或氟伏沙明使用:HR 0.814(95%CI 0.676-0.98)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether bisphosphonate use increases the risk of age-related macular degeneration (AMD), thereby providing evidence for the involvement of the NLRP3 inflammasome in AMD pathogenesis. METHODS: Retrospective cohort study among US veterans who had undergone dual-energy x-ray absorptiometry (DEXA) scans. Time-dependent Cox models were used to assess the association between cumulative bisphosphonate exposure and AMD incidence. Propensity score matching was applied to balance characteristics between bisphosphonate users and nonusers. A secondary analysis examined the impact of NLRP3 inhibitors (fluoxetine and fluvoxamine) on AMD risk among bisphosphonate users. RESULTS: After propensity score matching, each additional year of bisphosphonate use was associated with a 4.7% increased hazard of AMD (hazard ratio [HR], 1.047; 95% confidence interval [CI], 1.020-1.074). In the secondary analysis, fluoxetine or fluvoxamine use among bisphosphonate users was linked to a reduced hazard of incident AMD (HR, 0.814; 95% CI, 0.676-0.98) in the matched sample. CONCLUSIONS: Bisphosphonate use increases AMD risk, while NLRP3 inhibitors mitigate this effect. These findings support the hypothesis that the NLRP3 inflammasome is involved in AMD pathogenesis and represents a potential therapeutic target.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Magagnoli J, Cummings T, Hardin JW, et al. NLRP3 Activation With Bisphosphonate Use and the Risk of Incident Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2025. PMID: 40094655. doi:10.1167/iovs.66.3.32

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。